非小细胞肺癌患者血清中p53蛋白检测的临床意义

姚坚, 陈金亮, 陶一江, 陈建荣

姚坚, 陈金亮, 陶一江, 陈建荣. 非小细胞肺癌患者血清中p53蛋白检测的临床意义[J]. 实用临床医药杂志, 2012, (17): 43-45.
引用本文: 姚坚, 陈金亮, 陶一江, 陈建荣. 非小细胞肺癌患者血清中p53蛋白检测的临床意义[J]. 实用临床医药杂志, 2012, (17): 43-45.
YAO Jian, CHEN Jin-liang, TAO Yi-jiang, CHEN Jian-rong. Clinical significance of measuring p53 protein in serum of patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2012, (17): 43-45.
Citation: YAO Jian, CHEN Jin-liang, TAO Yi-jiang, CHEN Jian-rong. Clinical significance of measuring p53 protein in serum of patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2012, (17): 43-45.

非小细胞肺癌患者血清中p53蛋白检测的临床意义

基金项目: 中国高校医学期刊临床专项资金
详细信息
  • 中图分类号: R734.2

Clinical significance of measuring p53 protein in serum of patients with non-small cell lung cancer

  • 摘要: 目的 研究非小细胞肺癌(NSCLC)患者血清中p53蛋白检测的临床意义.方法 收集非小细胞肺癌(NSCLC)患者及体检健康者的血清,采用双抗体夹心生物素-亲和素酶联免疫吸附方法(ABC-ELISA)测定血清中p53蛋白水平.结果 手术组手术前血清中p53蛋白水平与手术后相比,差异有统计学意义(P<0.01);化疗有效组患者血清中p53蛋白水平均低于化疗前和化疗无效组,差异有统计学意义(P<0.01).结论 检测血清中p53蛋白水平,对NSCLC的诊断、治疗效果评价和预后估计有一定的临床意义.
  • Collins L G, Haines C, Perkel R. Lung cancer:diagnosis and management [J]. American Family Physician, 2007(1):56.
    Douillard J Y, Rosell R, Delena M. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-ⅢA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association[ANITA]):a randomised controlled trial [J]. Lancet Oncology, 2006(9):719.
    Lee S O, Andey T, Jin U H. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53 [J]. Oncogene, 2012, (27):3310.
    徐振晔, 杨宇飞. 肺癌中西医综合治疗 [M]. 北京:人民卫生出版社, 2002.815.
    Sinthupibulyakit C, Ittarat W, St Clair W H. p53 Protects lung cancer cells against metabolic stress [J]. International Journal of Oncology, 2010(6):1575.
    Otsuki T, Kanno T, Fujita Y. A(3) Adenosine Receptor-Mediated p53-Dependent Apoptosis in Lu-65 Human Lung Cancer Cells [J]. Cellular Physiology and Biochemistry, 2012(1):210.
    古颖春, 苏天璐. bcl-2、p53蛋白在肺癌组织中的表达及其意义 [J]. 实用癌症杂志, 2007(4):409.doi: 10.3969/j.issn.1001-5930.2007.04.029.
    Astle M V, Hannan K M, Ng P Y. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage:implications for targeting mTOR during malignancy [J]. Oncogene, 2012, (15):1949.
    Kim J S, Lee C, Bonifant C L. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA [J]. Molecular and Cellular Biology, 2007(2):662.
    Li G, Zhao J, Peng X. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism [J]. Cancer Biotherapy and Radiopharmaceuticals, 2012(4):227.
    Gao W M, Mady H H, Yu G Y. Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung:unique spectra involving G to A transitions and G to T transversions in both histologic types [J]. Lung Cancer, 2003(2):141.
    Liu Y, Gao W, Siegfried J M. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers [J]. BMC Cancer, 2007.74.
    Ruano-Ravina A, Perez-Becerra R, Fraga M. Analysis of the relationship between p53 immunohistochemical expression and risk factors for lung cancer, with special emphasis on residential radon exposure [J]. Annals of Oncology, 2008(1):109.
计量
  • 文章访问数:  152
  • HTML全文浏览量:  29
  • PDF下载量:  7
  • 被引次数: 0
出版历程
  • 发布日期:  2013-01-15

目录

    /

    返回文章
    返回